Furthermore, programmed cell death protein 1 (PD-1) inhibitors, such as nivolumab and pembrolizumab, have been approved for treating recurrent and metastatic HNSCC (5–7). This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.